Bvf Inc Nuvalent, Inc. Transaction History

Bvf Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$7.4 - $15.07 $7.23 Million - $14.7 Million	976,864 Added 141.69%	1,666,282 $22.6 Million
Q1 2022 May 16, 2022	BUY	$11.65 - $19.57 $2.81 Million - $4.71 Million	240,906 Added 53.71%	689,418 $9.58 Million
Q3 2021 Nov 15, 2021	BUY	$18.25 - $38.35 $8.19 Million - $17.2 Million	448,512 New	448,512 $10.1 Million

209

59.5M

450K

619K

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $3.62B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

Stay updated on Bvf Inc with notifications on news.